Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Anemia

Free Subscription Articles published in JAMA Retrieve available abstracts of 26 articles: HTML format

Single Articles

February 2023
1. HARRIS E
   FDA Approves First Oral Treatment for Kidney Disease-Induced Anemia.
   JAMA. 2023 Feb 15. doi: 10.1001/jama.2023.1556.
   PubMed    
   
   
   
2. LARKIN HD
   Sickle Cell Disease Gene Therapy Trial Paused.
   JAMA. 2023;329:364.
   PubMed    
   
   
   November 2022
3. VLACHADIS N, Vrachnis N
   A Review of Sickle Cell Disease.
   JAMA. 2022;328:1979.
   PubMed    
   
   
   
4. KAVANAGH PL, Fasipe T, Wun T
   A Review of Sickle Cell Disease-Reply.
   JAMA. 2022;328:1979-1980.
   PubMed    
   
   
   
5. LARKIN HD
   Gene Therapy for Sickle Cell Disease, beta-Thalassemia Enters Regulatory Reviews.
   JAMA. 2022;328:1798.
   PubMed    
   
   
   October 2022
6. KUEHN BM
   Children With Sickle Cell Anemia Not Receiving Recommended Care.
   JAMA. 2022;328:1583-1584.
   PubMed    
   
   
   September 2022
7. RUBIN R
   New Gene Therapy for beta-Thalassemia.
   JAMA. 2022;328:1030.
   PubMed    
   
   
   August 2022
8. SLOMSKI A
   Sickle Cell Trait Associated With Kidney Failure and COVID-19 Death.
   JAMA. 2022;328:415.
   PubMed    
   
   
   July 2022
9. KAVANAGH PL, Fasipe TA, Wun T
   Sickle Cell Disease: A Review.
   JAMA. 2022;328:57-68.
   PubMed     Abstract available
   
   
   June 2022
10. OSHIMA T, Kinjo K, Kinjo M
    Chronic Abdominal Pain and Anemia in a 59-Year-Old Man.
    JAMA. 2022 Jun 24. pii: 2793812. doi: 10.1001/jama.2022.9194.
    PubMed    
    
    
    February 2022
11. SLOMSKI A
    Oral Daprodustat Treats Anemia in Chronic Kidney Disease.
    JAMA. 2022;327:710.
    PubMed    
    
    
    October 2021
12. ABOU BAKER NM, Davis AM
    Gastrointestinal Evaluation of Iron Deficiency Anemia.
    JAMA. 2021;326:1624-1625.
    PubMed    
    
    
    September 2021
13. KENTER MJH, Cohen AF
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:974-975.
    PubMed    
    
    
    
14. GURKAN UA
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:975.
    PubMed    
    
    
    
15. CASELLA JF, Kronsberg SS, Gorney RT
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply.
    JAMA. 2021;326:975-976.
    PubMed    
    
    
    July 2021
16. ZHANG H, Kilaru AS, Meisel ZF, Bao Y, et al
    Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis.
    JAMA. 2021;326:274-276.
    PubMed    
    
    
    June 2021
17. SATO T, Terada R, Ikeda T
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia.
    JAMA. 2021;325:2505-2506.
    PubMed    
    
    
    
18. DUCROCQ G, Simon T, Steg PG
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-Reply.
    JAMA. 2021;325:2506-2507.
    PubMed    
    
    
    May 2021
19. 
    Foreign Letters: London.
    JAMA. 2021;325:1907.
    PubMed    
    
    
    April 2021
20. ZYLKE J
    Poloxamer 188 for Sickle Cell Disease.
    JAMA. 2021;325:1524.
    PubMed    
    
    
    
21. CASELLA JF, Barton BA, Kanter J, Black LV, et al
    Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    JAMA. 2021;325:1513-1523.
    PubMed     Abstract available
    
    
    
22. EHRENREICH H, Neubauer AP, Miskowiak K
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years.
    JAMA. 2021;325:1470-1471.
    PubMed    
    
    
    
23. NATALUCCI G, Bucher HU, Fauchere JC
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years-Reply.
    JAMA. 2021;325:1471-1472.
    PubMed    
    
    
    February 2021
24. DUCROCQ G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al
    Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
    JAMA. 2021;325:552-560.
    PubMed     Abstract available
    
    
    January 2021
25. ABBASI J
    Promising Strategies for Sickle Cell Disease and beta-Thalassemia.
    JAMA. 2021;325:121.
    PubMed    
    
    
    December 2020
26. NATALUCCI G, Latal B, Koller B, Ruegger C, et al
    Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
    JAMA. 2020;324:2324-2327.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: